Your search for rivaroxaban returned 148 results

Your search for rivaroxaban returned 148 results

Sort Results:

Relevant Recent

Xarelto as Effective as Standard of Care for DVT/PE

A new pooled analysis of the Phase 3 EINSTEIN trial program showed that Xarelto had similar efficacy as the standard of care in reducing the risk of DVT and PE in patients with symptomatic DVT/PE.
Drugs in the Pipeline

Xarelto sNDA Submitted for Two New Vascular Indications

For this group the risk of stroke was reduced by 42% (HR 0.58; 95% CI, 0.44-0.76; P<0.001), CV death by 22% (HR 0.78; 95% CI, 0.64-0.96; P=0.02) and heart attack by 14% (HR 0.86; 95% CI, 0.70-1.05; P=0.14).

Xarelto Efficacy Supported by New Real-World Data

Janssen and Bayer announced new data from two real-world studies that confirmed the positive benefit-risk profile of Xarelto (rivaroxaban) for the treatment of venous thromboembolism (VTE) and reducing the risk of recurrence.
Clinical Charts

Thromboembolic Disorder Assessment: DVT/PE

Risk factors, prevention strategies, signs & symptoms, and general treatment options for deep vein thrombosis (DVT) and pulmonary embolism (PE).